These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3374026)

  • 1. Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.
    Walter-Sack I; de Vries JX; Ittensohn A; Kohlmeier M; Weber E
    Klin Wochenschr; 1988 Feb; 66(4):160-6. PubMed ID: 3374026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biliary excretion of benzbromarone and its hydroxilated main metabolites in humans.
    Walter-Sack I; de Vries JX; Ittensohn A; Raedsch R
    Eur J Med Res; 1998 Feb; 3(1-2):45-9. PubMed ID: 9512967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man.
    De Vries JX; Walter-Sack I; Ittensohn A; Weber E
    Xenobiotica; 1989 Dec; 19(12):1461-70. PubMed ID: 2618093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of hypouricemic effect of benzbromarone.
    Sinclair DS; Fox IH
    J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of benzbromarone: a new uricosuric drug.
    Sorensen LB; Levinson DJ
    Arthritis Rheum; 1976; 19(2):183-90. PubMed ID: 1259799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
    Yu TF
    J Rheumatol; 1976 Sep; 3(3):305-12. PubMed ID: 978666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?
    Walter-Sack I; de Vries JX; von Bubnoff A; Pfleilschifter V; Raedsch R
    Eur J Med Res; 1995 Oct; 1(1):16-20. PubMed ID: 9392688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite.
    de Vries JX; Walter-Sack I; Ittensohn A; Weber E; Empl H; Gresser U; Zöllner N
    Clin Investig; 1993 Nov; 71(11):947-52. PubMed ID: 8312690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic fate of the thrombolytic agent benzarone in man: comparison with the rat and dog.
    Wood SG; John BA; Chasseaud LF; Bonn R; Grote H; Sandrock K; Darragh A; Lambe RF
    Xenobiotica; 1987 Jul; 17(7):881-96. PubMed ID: 3660858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of benzbromarone on fasting-hyperuricemia as a model (author's transl)].
    Schräpler P; Kleinschmidt A; Haese E
    Med Klin; 1978 Jun; 73(23):861-6. PubMed ID: 661730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].
    Schulz E; Schräpler P; Kleinschmidt A
    Med Klin; 1978 Feb; 73(7):240-6. PubMed ID: 628361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study.
    Zürcher RM; Bock HA; Thiel G
    Nephrol Dial Transplant; 1994; 9(5):548-51. PubMed ID: 8090336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Action of benzbromarone on the renal excretion of allantoin in normouricemic and hyperuricemic humans (author's transl)].
    Janzen D; Mertz DP; Scheiffele E; Kühnhold O
    Klin Wochenschr; 1977 Nov; 55(21):1071-3. PubMed ID: 926719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of purine catabolism by benzbromarone in isolated rat liver cells. Comparison with allopurinol and probenecid.
    Rodilla F; Sanchez-Beltran MJ; Izquierdo R; Gomez-Ruiz MD; Cabo J
    Biochem Pharmacol; 1988 Oct; 37(19):3561-3. PubMed ID: 3178870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity.
    Kaufmann P; Török M; Hänni A; Roberts P; Gasser R; Krähenbühl S
    Hepatology; 2005 Apr; 41(4):925-35. PubMed ID: 15799034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases in whom pyrazinamide does not inhibit the uricosuric action of benzbromarone.
    Yamamoto T; Moriwaki Y; Takahashi S; Suda M; Agbedana EO; Higashino K
    Nephron; 1992; 61(4):432-4. PubMed ID: 1501741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal excretion of purine bases. Effects of probenecid, benzbromarone and pyrazinamide.
    Yamamoto T; Moriwaki Y; Takahashi S; Hada T; Higashino K
    Nephron; 1988; 48(2):116-20. PubMed ID: 3344050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of benzarone in human plasma and urine by high-performance liquid chromatography and gas chromatography-mass spectrometry. Identification of the conjugates.
    de Vries JX; Walter-Sack I; van de Loo A; Kocher J
    J Chromatogr; 1986 Oct; 382():167-74. PubMed ID: 3782383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles.
    Walter-Sack I; de Vries JX; Ittensohn A; Weber E
    Eur J Clin Pharmacol; 1990; 39(6):577-81. PubMed ID: 2095343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.